Skip Nav Destination
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
Issue Archive
Table of Contents
INSIDE BLOOD COMMENTARIES
BLOOD WORK
PLENARY PAPER
Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan
Zhi-Jian Liu,Karin M. Hoffmeister,Zhongbo Hu,Donald E. Mager,Sihem Ait-Oudhia,Marlyse A. Debrincat,Irina Pleines,Emma C. Josefsson,Benjamin T. Kile,Joseph Italiano, Jr,Haley Ramsey,Renata Grozovsky,Peter Veng-Pedersen,Chaitanya Chavda,Martha Sola-Visner
CLINICAL TRIALS AND OBSERVATIONS
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Clinical Trials & Observations
Jennifer R. Brown,John C. Byrd,Steven E. Coutre,Don M. Benson,Ian W. Flinn,Nina D. Wagner-Johnston,Stephen E. Spurgeon,Brad S. Kahl,Celeste Bello,Heather K. Webb,Dave M. Johnson,Sissy Peterman,Daniel Li,Thomas M. Jahn,Brian J. Lannutti,Roger G. Ulrich,Albert S. Yu,Langdon L. Miller,Richard R. Furman
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
Clinical Trials & Observations
Brad S. Kahl,Stephen E. Spurgeon,Richard R. Furman,Ian W. Flinn,Steven E. Coutre,Jennifer R. Brown,Don M. Benson,John C. Byrd,Sissy Peterman,Yoonjin Cho,Albert Yu,Wayne R. Godfrey,Nina D. Wagner-Johnston
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
Clinical Trials & Observations
Ian W. Flinn,Brad S. Kahl,John P. Leonard,Richard R. Furman,Jennifer R. Brown,John C. Byrd,Nina D. Wagner-Johnston,Steve E. Coutre,Don M. Benson,Sissy Peterman,Yoonjin Cho,Heather K. Webb,David M. Johnson,Albert S. Yu,Roger G. Ulrich,Wayne R. Godfrey,Langdon L. Miller,Stephen E. Spurgeon
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome
Clinical Trials & Observations
Annamaria Brioli,Hannah Giles,Charlotte Pawlyn,John P. Campbell,Martin F. Kaiser,Lorenzo Melchor,Graham H. Jackson,Walter M. Gregory,Roger G. Owen,J. Anthony Child,Faith E. Davies,Michele Cavo,Mark T. Drayson,Gareth J. Morgan
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
e-blood
Raajit Rampal,Fatima Al-Shahrour,Omar Abdel-Wahab,Jay P. Patel,Jean-Philippe Brunel,Craig H. Mermel,Adam J. Bass,Jennifer Pretz,Jihae Ahn,Todd Hricik,Outi Kilpivaara,Martha Wadleigh,Lambert Busque,D. Gary Gilliland,Todd R. Golub,Benjamin L. Ebert,Ross L. Levine
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
TRANSFUSION MEDICINE
TRANSPLANTATION
Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation
Richard Aplenc,Mei-Jie Zhang,Lillian Sung,Xiaochun Zhu,Vincent T. Ho,Kenneth Cooke,Christopher Dvorak,Gregory Hale,Luis M. Isola,Hillard M. Lazarus,Philip L. McCarthy,Richard Olsson,Michael Pulsipher,Marcelo C. Pasquini,Nancy Bunin,on behalf of the Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research,on behalf of the Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research,on behalf of the Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research,on behalf of the Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research,on behalf of the Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research,on behalf of the Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research,on behalf of the Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research,on behalf of the Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research,on behalf of the Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research,on behalf of the Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research,on behalf of the Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research,on behalf of the Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research,on behalf of the Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research,on behalf of the Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research,on behalf of the Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research
-
Cover Image
Cover Image
Megakaryocyte maturation and platelet lifespan in neonates. See the article by Liu et al on page 3381.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals